ClinicalTrials.gg
TerminatedNCT03680560Updated Mar 31, 2020

Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers

A Phase 1 interventional study of ACTR T Cell Product and Trastuzumab in Solid Tumor and HER-2 Protein Overexpression, sponsored by Cogent Biosciences, Inc.. Terminated at 6 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-03-31.

Sponsored by Cogent Biosciences, Inc. · Phase 1, Interventional, and Treatment

Why this study was terminated
Business Reasons

From the registry’s dates

  • Primary completion was Mar 2020, 6 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 374 studies testing trastuzumab in Breast Neoplasms — 57 open to participants now, 86 under way, 5 of them phase 3. Trastuzumab · Breast Neoplasms.

Enrollment
341st of 366
6 · median 61
Started
2019
with 14 others
Phase 1
21 of 374
3 open now
Registered
264th of 374
by date

Among the 374 studies testing trastuzumab in Breast Neoplasms, this one is the 341st largest by enrollment of the 366 interventional ones that give a count, is one of 15 that started in 2019, is one of 21 in phase 1, and was the 264th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

57 of the 374 studies testing trastuzumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About trastuzumab

Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 374 studies testing trastuzumab in Breast Neoplasms, or all of them as a file.
02

Study summary

This is a Phase 1, open-label, multi-center study to assess safety and determine the recommended phase 2 dose (RP2D) of ACTR T cell product (ACTR707 or ACTR087) in combination with trastuzumab, following lymphodepleting chemotherapy in subjects with HER2-positive advanced malignancies.

03

Conditions studied

  • Solid Tumor
  • HER-2 Protein Overexpression

Keywords

  • HER2
  • ACTR
  • ACTR087
  • ACTR707
  • T cell
  • T cell product
  • adoptive T cells
  • gene therapy
  • breast cancer
  • gastric cancer
  • gastro esophageal cancer
  • immunotherapy
  • solid tumor
  • adenoid cystic carcinoma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed written obtained prior to study procedures
  • -confirmed Her2 positive advanced solid tumor with documented disease progression during or immediately following the immediate prior therapy, or within 6 months of completing therapy for subjects with breast cancer
  • Subjects must have previously received adequate standard therapy for treatment of their malignancy

    • For those with breast cancer, must have received -directed therapy including trastuzumab, pertuzumab and ado-trastuzumab in any breast cancer disease setting
    • For those with advanced gastric cancer, adequate prior treatment with HER2-directed chemotherapy is required
  • At least 1 by
  • Able to provide fresh tumor or archived block specimen taken since time of most recent anti-HER2 mAb-directed therapy
  • of 0 or 1
  • ≥ 6 months
  • ≥ 50% by MUGA or ECHO
  • Absolute neutrophil (ANC) count ≥ 1500/ µL
  • count ≥ 100,000/µL
  • ≥ 9g/dL
  • Estimated >30mL/min/1.73m2

Exclusion criteria

Exclusion Criteria:

  • glioblastoma multiforme or other primary CNS tumors are excluded
  • cardiac disease
  • clinically significant active infection
  • clinical history, prior diagnosis, or overt evidence of disease
  • current use of more than 5mg/day of prednisone (or an equivalent )
  • Prior treatment as follows:

    • prior cumulative doxorubicin dose greater than or equal to 300 mg/m\^2 or equivalent
    • chemotherapy within 2 weeks of enrollment
    • external beam radiation within 2 weeks of enrollment (28 days if CNS-directed therapy)
    • any monoclonal antibody (mAb) or other protein therapeutic containing Fc-domains within 4 weeks of enrollment
    • pertuzumab within 4 months of enrollment
    • Experimental agents within 3 half-lives or 28 days prior to enrollment, whichever is shorter
    • hematopoietic stem cell transplant (HSCT)
    • prior infusion of a genetically modified therapy
  • Pregnant or breastfeeding
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    ACTR T cell product in combination with trastuzumab

    Biological: ACTR T Cell Product · Drug: Trastuzumab

Interventions

  • BiologicalACTR T Cell Product

    Autologous Antibody-Coupled T Cell Receptor (ACTR) T Cell Product (ACTR707 or ACTR087)

  • monoclonal antibody targeting HER2

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of ACTR T cell product with trastuzumab as assessed by committee review of dose limiting toxicities (DLTs), incidence and severity of adverse events (AEs) and clinically significant abnormalities of laboratory values

    Time frame: 42 days

  2. Determination of recommended phase 2 dose (RP2D) regimen

    Review of DLTs, maximum tolerated dose (MTD), incidence and severity of AEs and clinically significant abnormalities of laboratory values

    Time frame: 42 days

Secondary outcomes

  1. Anti-tumor activity as measured by overall response rate (ORR) per iRECIST

    Time frame: 52 weeks

  2. Anti-tumor activity as measured best overall response (BOR)

    Time frame: 52 weeks

  3. Anti-tumor activity as measured by duration of response (DOR)

    Time frame: 52 weeks

  4. Anti-tumor activity as measured by progression-free survival (PFS)

    Time frame: 52 weeks

  5. Anti-tumor activity as measured by overall survival (OS)

    Time frame: 52 weeks

  6. Assessment of persistence of ACTR as measured by flow cytometry

    Time frame: 52 weeks

  7. Assessment of persistence of ACTR as measured by quantitative polymerase chain reaction (qPCR)

    Time frame: 52 weeks

  8. Assessment of ACTR phenotype and function as measured by flow cytometry

    Time frame: 52 weeks

  9. Assessment of induction of inflammatory markers and cytokines/chemokines after ACTR T cell product administration

    Levels of inflammatory markers, cytokines/chemokines in blood

    Time frame: 52 weeks

  10. Trastuzumab pharmacokinetics (PK)

    trastuzumab serum concentration, Area Under the Curve (AUC), trough levels

    Time frame: 52 weeks

07

Study locations

6 sites
  • Yale Smilow Cancer Hospital
    New Haven, Connecticut 06511, United States
  • Miami University Cancer Center
    Miami, Florida 33136, United States
  • The Ohio State University
    Columbus, Ohio 43210, United States
  • Sarah Cannon Research Institute/Tennessee Oncology, PLLC
    Nashville, Tennessee 37203, United States
  • Baylor Scott & White Medical Center
    Dallas, Texas 75201, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
08

References and documents

Related links

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2019 to primary completion in Mar 2020, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2018
First posted
Sep 21, 2018
StartActual
Mar 13, 2019
Primary completionActual
Mar 12, 2020
CompletionActual
Mar 12, 2020
Last update
Mar 31, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03680560
Lead sponsor
Cogent Biosciences, Inc.
Responsible party
Sponsor
First posted
Sep 21, 2018
Start date
Mar 13, 2019
Primary completion
Mar 12, 2020
Completion
Mar 12, 2020
Last update
Mar 31, 2020

Study contacts

Glen Weiss, MD
study director · Cogent Biosciences, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab

Start the discussion